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anemia (5.4%), coronary atherosclerosis (4.5%), and congestive heart failure (3.5%).
Similarly, the most commonly prescribed medications among CKD patients were 
furosemide (16.3), atorvastatin (9.1%), lisinopril (9.0%), amlodipine (9%), aspirin
(8.6%), levothyroxine (7.9%), metaraminol (7.8%), insulin (7.4), atenolol (6.1%),
and potassium replacement solutions (5.3%). CONCLUSIONS: Our study identiﬁ es
the most common co-morbidities diagnosed among CKD patients. Early screening and 
treatment for these conditions may help lower the rate of progression of CKD.
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OBJECTIVES: Assess the impacts of the preventive treatment of patients suffering
from recurring cystitis by means of a standard dry cranberry extract. METHODS: An
observational, longitudinal and prospective assessment by Urologists as part of their 
professional everyday activity. RESULTS: Ninety-two female patients, with an average 
age of 53.9–18.9 years, were included in the study. These patients had been monitored
for a period of 7 months (median). Before inclusion, 89 of the patients (96.7%) had
been offered an antibiotherapy. Depending on the patients, the factors that triggered 
their cystitis most frequently were: sexual relations (58.0%), alcohol consumption 
(27.6%) and diarrhoea (19.3%). The frequency and urgency of urination, the burning
sensation upon urination, the inability to completely empty the bladder and sensation 
of heaviness in the pubic region were the ﬁ ve symptoms assessed every three weeks. 
On inclusion, the scores for each symptom were, respectively: 6.2; 6.5; 6.1; 3.1 and
4.6. The overall score was 28.9. After 3 months, the scores for each symptom were, 
respectively: 1.6; 1.9; 1.9; 0.4 and 0.7. The overall score was 7.1. The evolution of 
the overall score (p  0.001) was signiﬁ cant, as was that of each respective symptom.
The prevalence of cystitis at 3 months was 47.6% (versus 96.7%) on inclusion. 
CONCLUSIONS: The prevalence of urinary problems in subjects suffering from
recurring cystitis was halved after 3 months of treatment by means of a standard dry
cranberry extract (96.7% versus 47.6%).
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CASE STUDY OF CREATING A FORMULARY MANAGEMENT PROCESS
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ORGANIZATION: Bangalore Institute of Oncology (BIO). PROBLEM OR ISSUE 
ADDRESSED: Pharmacy and Therapeutics committee’s responsibilities consist
of developing policies and frameworks to develop an effective formulary taking 
into account both efﬁ cacy and cost considerations. In the Indian pharmaceutical 
environment, multiple manufactures compete for market share, within a single institu-
tion itself, creating inefﬁ ciencies in inventory management and the overall pharma-
ceutical budget. GOALS: The purpose of this project was to create a formulary for 
the Bangalore Institute of Oncology (BIO), taking into account both cost and efﬁ cacy 
considerations, while still maintaining physician preferences and autonomy. A prelimi-
nary ABC analysis, also known as a Pareto analysis, was conducted to identify items 
which have a signiﬁ cant impact on the overall inventory costs and well as, identify
and rank areas for improvement and management interventions. OUTCOMES 
ITEMS USED IN THE DECISION: The institutional ABC analysis was conducted for
the period of October 2006 to September 2007. Pharmaceutical items were valued 
(item cost multiplied by quantity issued/consumed in period) with the results subse-
quently ranked. IMPLEMENTATION STRATEGY: The total pharmacy budget for 
the ﬁ scal year was 15.89 Crore Rupees (Rs) (3.96 million US dollars, based on 40:1
exchange rate) with a resulting margin of 3.51 Crore Rupees (Rs) ($877,500), which 
consisted of 1033 different products from 247 manufacturers. The ABC analysis
revealed that 48 medications made up 85% of the total budget, with bortezomib being
the highest oncology contributor and meropenem being the highest non-oncology 
contributor. Analysis of purchases within the 35 oncology products revealed that there
were 29 manufacturers with 95 different brands, and for the 13 non oncology prod-
ucts, there were 14 manufacturers with 20 different brands. Based on this analysis,
consolidation of drug products and drug manufacturers were considered as an inter-
vention for formulary management by the Pharmacy and Therapeutics Committee. 
Three different options were considered by the committee. Option 1 consolidates to
only a single brand based on the highest margin, which would improve the present 
margin by 46% from 3.51 Crore Rs ($877,500) to 5.15 Crore Rs ($1,287,500).
Option 2 consolidates to having two brands, one from the preferred vendor with the 
highest margin and the other from the innovator/premium vendor, which would
improve the margin by 36% to 4.76 Crore Rs ($1,119,000). Option 3 consolidates 
to three brands: the preferred vendor with the highest margin, the lowest cost brand 
from the patient’s perspective, and the innovator/premium vendor brand, which would 
improve the margin by 24% to 4.36 Crore Rs ($1,090,000). Option 3 was chosen as
the basis for creating the institutional formulary, due to physician ﬂ exibility, patient
affordability, and improvements to the margin. RESULTS: The pharmaceutical 
company Dr. Reddy was selected as the preferred vendor for the creation of the for-
mulary and Option 3 was applied to all of the following pharmaceuticals(N): mono-
clonal antibodies(6); oral chemotherapy(23); intravenous chemotherapy(31); hormonal 
agents (9); and supportive care agents(13), for a total of 82 separate chemical entities.
Of the total 82 chemical entities, 43 (52.4%) have one brand available, 29 (35.4%) 
have two brands available, and 10 (12.2%) have three brands available. The preferred
vendor was utilized for 18 of these products. If the same total quantity is purchased 
again in 2008, the total purchase cost will be 54.15 Crore Rs ($13,538,047) with a 
resulting margin of 20.13 Crore Rs ($5,033,454). LESSONS LEARNED: Consolida-
tion of the pharmaceutical products and creation of a formulary results in higher than 
expected margin, even when the same purchase quantity is applied. Market competi-
tion forces appear to work better in an environment of a closed formulary system.
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ORGANIZATION Vila Velha Hospital (VVH). Vila Velha, Espirito Santo, Brazil. 
PROBLEM OR ISSUE ADDRESSED To assure client space and ﬁ delity in the market 
of health services through novel strategies able to supply health care providers 
with information about their clients and service costs at hospitals in the metropolitan
region of Vitoria-ES, Brazil. GOALS 1-Semestral increase of 30% in the number of 
clients referred for consultation at VVH and their ﬁ delity as a result of the good quality 
of services. 2-Semestral increase of 20% in VVH services required from health care
providers. OUTCOMES ITEMS USED IN THE DECISION Data from a search 
regarding the opinion of clients and health care providers about the ideal health ser-
vices were considered in the ﬁ nal decision. This information was obtained from 
PROAHSA (Program of Advanced Studies in Hospital Administration and Health
Systems) and from CHQ (Program of Quality Control of Medical Services). IMPLE-
MENTATION STRATEGY Analysis of patient stay at the hospital and its total cost,
considering age, site and disease of the client at VVH. All diseases described in ICD 
(International Classiﬁ cation of Diseases) were classiﬁ ed in acute, chronic and acciden-
tal, according to the duration of disease, loss of function, treatment type and length, 
and recurrence probability. RESULTS The data obtained allowed the comprehension
of characteristics of clients seen at VVH, and also allowed the proper estimation of 
treatment costs for various pathologies and the development of a cost curve per
pacient, materials and medications. LESSONS LEARNED The understanding of client 
speciﬁ cities allows price negotiation in a more secure and transparent way for both 
the hospital and the health care providers, and allows a more efﬁ cient handling of 
ﬁ nancial resources.
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ORGANIZATION: Agency of Health Technology Assessment Warsaw, Poland.
PROBLEM OR ISSUE ADDRESSED: Need to supply safe and most effective drugs, 
services and devices for publicly insured inhabitants through different mechanisms of 
spending public sources. GOALS: (1) Development a health technology assessment
procedures and incorporating its results into decision-making process of using public 
sources in Polish Health Care System. (2) Setting priorities of assessing areas – accord-
ing to health beneﬁ ts ﬁ nanced from public means reimbursement criteria. (3) Providing 
sufﬁ cient information for making decisions. OUTCOMES ITEMS USED IN THE
DECISION: There were different measurements performed during planning, imple-
menting and revising process of development AHTAPol. Measures were elaborated
parallel by national and international experts. IMPLEMENTATION STRATEGY:
AHTAPol was establish on 2006 as a governmental organization whose aims are:
assessment of medical procedures – health technologies; elaboration, veriﬁ cation, 
gathering and dissemination of information about HTA results of such assessments,
methodology and support of guidelines development made based on them; elaboration 
of recommendations for the Minister of Health concerning ﬁ nancing health technolo-
gies from public means (the role of the Consultative Council); collaboration with other 
authorities and organization acting in health care system and performing other duties
delegated by the Minister of Health (MoH) of Poland. One of the ﬁ rst actions of 
AHTAPol was related to delegation of MoH for development the basic beneﬁ t 
package. For the estimation of budget needed to services included into beneﬁ t package 
the costs calculating program was designed and pilot activities were performed. 
And ﬁ nally drug dossiers assessment and appraisal process led to recommendation 
for decision of MoH. These actions were supported by development department 
focused on analytical part and independent body – Consultative Council acting as an
appraisal committee RESULTS: Involvement of AHTAPol in activities related to based 
beneﬁ t package were limited to development of central medical services (with descrip-
tion of diagnoses and professional specialties) data-base. Costs calculation of these 
services was not started. Engagement of nationally recognized experts supported by
AHTAPol ended on development national cost calculating project. This project most 
probably will start in 2009. The most expected by policy-makers, public and clinicians 
activities of AHTAPol nowadays is involvement on the process of drug and modern 
medical technology reimbursement by elaboration of recommendations for decision 
of MoH. Organizational respond of AHTAPol resulted at the number of recommenda-
tion: 13 in 2007 and 81 in 2008. In 2009 is planed over 300. LESSONS LEARNED:
